Clinical OMICS

NOV-DEC 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1040438

Contents of this Issue

Navigation

Page 18 of 51

www.clinicalomics.com November/December 2018 Clinical OMICs 17 resent more than 60 locations with roughly 225 practicing physicians. A core principal of OneOncology is as it grows into a nationwide network of community cancer centers, that its mission will continue to be driven and directed by the physicians themselves. To that end, the physician leaders of the three founding practices—Jeff Patton, M.D., CEO of Tennessee Oncology; Jeff Vacirca, M.D., CEO of New York Cancer & Blood Spe- cialists; and Lee Schwartzberg, M.D., executive director of West Cancer Center—serve on the company's board of directors. According to Bahl, there will always be seats on the board for physicians from its network of practices, as they bring real-world knowledge of running a community oncology center. OneOncology executives said the company will sup- port its member practices in three fundamental ways: via economies of scale including drug and pharmacy pricing, back office operations, and revenue cycle management; economies of "intelligence" that allow the sharing of care pathways, clinical decision support, and supporting patient experience; and access to capital to allow practices to invest in new technologies or undergo expansion in ways that best serve patients in their regions. Creating a New Model of Care According to Bahl, the concept for OneOncology was not via an epiphany, rather it was a series of conversations over the course of couple of years about the challenges commu- nity oncology centers faced that would likely become more significant pressure points in ensuing years. "It was grounded in Nat Turner and Robin Shah of Flat- iron [Health] having conversations with the two Jeffs (Patton of Tennessee Oncology, and Vacirca of New York Cancer & Blood Specialists)," Bahl noted. "[Patton] said that he loved Flatiron's technology, but that he was going to need more than the technology to help him with the challenges he saw coming. Nat and Robin said they had spoken with a number of other practices who had told them the same thing." With the concept of helping community practices more broadly than providing technology assistance, the initial players began conversations with the investors at General Atlantic who were also mulling a similar opportunity. As the plan developed, David Chernow, now president and CEO of long-term care company Select Medical—who also was also a key player at US Oncology—joined as chairman of the board, as well as Bahl whose experience includes a stint at CVS and at Emdeon, a provider of software for med- ical claims and medical data, and Shah who had worked at Flatiron since its founding in 2012. "My father passed away at a relatively young age from cancer and I came away from that deeply admiring the clini- cians that treated him, and deeply frustrated by the admin- istrative process that my family and I had to go through to care for my dad," said Bahl. "We believed that we could equip community cancer centers with more than just the tools from Flatiron to help them succeed. Added Shah, who moved from Flatiron to OneOncology as a fouding partner and chief marketing officer: "I used to run a community cancer center before I joined Flatiron. I saw the company go from three people to more than 800. One of the most exciting things was the company was a bunch of young, smart and energetic people coming to dis- rupt the space of oncology. I see this as round two." Enabling Sharing of Best Practices "When you are part of a community cancer practice, there are a lot of great things you do, but also opportunities to be better in certain areas. It is very likely that at another practice, someone has perfected or has a great process for the things you can improve," said Shah. "Currently, the way people try to collaborate to improve different aspects of their practices are through state societies, national conferences, or loose affili- ations with other organizations. But those only happen once, twice, or three times per year." A key underpinning of OneOncol- ogy will be to leverage technology provided by Flatiron Health, namely it's OncoEMR, OncoAnalytics, and OncoTrials, as well as other tools. This (continued on next page)

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - NOV-DEC 2018